1
|
Rossi GC, Bodnar RJ. Interactive Mechanisms of Supraspinal Sites of Opioid Analgesic Action: A Festschrift to Dr. Gavril W. Pasternak. Cell Mol Neurobiol 2021; 41:863-897. [PMID: 32970288 DOI: 10.1007/s10571-020-00961-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 09/03/2020] [Indexed: 12/30/2022]
Abstract
Almost a half century of research has elaborated the discoveries of the central mechanisms governing the analgesic responses of opiates, including their receptors, endogenous peptides, genes and their putative spinal and supraspinal sites of action. One of the central tenets of "gate-control theories of pain" was the activation of descending supraspinal sites by opiate drugs and opioid peptides thereby controlling further noxious input. This review in the Special Issue dedicated to the research of Dr. Gavril Pasternak indicates his contributions to the understanding of supraspinal mediation of opioid analgesic action within the context of the large body of work over this period. This review will examine (a) the relevant supraspinal sites mediating opioid analgesia, (b) the opioid receptor subtypes and opioid peptides involved, (c) supraspinal site analgesic interactions and their underlying neurophysiology, (d) molecular (particularly AS) tools identifying opioid receptor actions, and (e) relevant physiological variables affecting site-specific opioid analgesia. This review will build on classic initial studies, specify the contributions that Gavril Pasternak and his colleagues did in this specific area, and follow through with studies up to the present.
Collapse
Affiliation(s)
- Grace C Rossi
- Department of Psychology, C.W. Post College, Long Island University, Post Campus, Brookville, NY, USA.
| | - Richard J Bodnar
- Department of Psychology, Queens College of the City University of New York, Flushing, NY, USA
- CUNY Neuroscience Collaborative, Graduate Center, CUNY, New York, NY, USA
| |
Collapse
|
2
|
Abstract
Opiates are among the oldest medications available to manage a number of medical problems. Although pain is the current focus, early use initially focused upon the treatment of dysentery. Opium contains high concentrations of both morphine and codeine, along with thebaine, which is used in the synthesis of a number of semisynthetic opioid analgesics. Thus, it is not surprising that new agents were initially based upon the morphine scaffold. The concept of multiple opioid receptors was first suggested almost 50 years ago (Martin, 1967), opening the possibility of new classes of drugs, but the morphine-like agents have remained the mainstay in the medical management of pain. Termed mu, our understanding of these morphine-like agents and their receptors has undergone an evolution in thinking over the past 35 years. Early pharmacological studies identified three major classes of receptors, helped by the discovery of endogenous opioid peptides and receptor subtypes-primarily through the synthesis of novel agents. These chemical biologic approaches were then eclipsed by the molecular biology revolution, which now reveals a complexity of the morphine-like agents and their receptors that had not been previously appreciated.
Collapse
Affiliation(s)
- Gavril W Pasternak
- Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065.
| | | |
Collapse
|
3
|
Docking studies suggest ligand-specific delta-opioid receptor conformations. J Mol Model 2008; 15:267-80. [PMID: 19052783 DOI: 10.1007/s00894-008-0396-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2008] [Accepted: 11/03/2008] [Indexed: 10/21/2022]
Abstract
An automated docking procedure was used to study binding of a series of delta-selective ligands to three models of the delta-opioid receptor. These models are thought to represent the three ligand-specific receptor conformations. Docking results are in agreement with point mutation studies and suggest that different ligands--agonists and antagonists--may bind to the same binding site under different receptor conformations. Docking to different receptor models (conformations) also suggests that by changing to a receptor-specific conformation, the receptor may open or close different binding sites to other ligands.
Collapse
|
4
|
Saitoh A, Yoshikawa Y, Onodera K, Kamei J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 2005; 182:327-34. [PMID: 16075288 DOI: 10.1007/s00213-005-0112-6] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2004] [Accepted: 06/20/2005] [Indexed: 11/26/2022]
Abstract
RATIONALE Recent studies have shown that endogenous opioid systems are associated with the regulation of emotional responses. In particular, it has been reported that delta-opioid receptors act naturally to inhibit stress and anxiety. OBJECTIVE The present study was designed to examine the possible involvement of opioid delta-receptor subtypes in the anxiety-related behavior in the elevated-plus-maze test. METHODS Six-week-old male Lewis rats were used. The total numbers of visits to the closed and open arms and the cumulative time spent and visits in the open arms were determined. Plasma corticosterone levels were measured by enzyme immunoassay. RESULTS Naltrindole (NTI), a delta-opioid receptor antagonist (3 mg/kg s.c.), induced a significant decrease in the percentages of time spent and visits in the open arms. Naltriben (NTB), a delta2-opioid receptor antagonist (3 mg/kg s.c.), but not 7-benzylidenenaltrexone, a delta1-opioid receptor antagonist, produced similar anxiety-related behaviors in the elevated plus-maze. These effects of NTI and NTB were antagonized by pretreatment with (+)-4-[(aR)-a-((2S,5R)-4-allyl-2,5-dimethyl-1piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80), a delta-opioid receptor agonist. Furthermore, after exposure to the elevated plus-maze, the maximal increase in the plasma corticosterone level in NTI-treated rats was clearly higher than that in vehicle-treated rats. However, when NTI and SNC80 were coadministered, higher levels of plasma corticosterone were not seen after exposure to the elevated plus-maze. CONCLUSION These results suggest that endogenous delta2-opioid-receptor-mediated systems are involved in the regulation of anxiety-related behaviors and might play a physiologically important role in the regulation of adrenocortical activity.
Collapse
Affiliation(s)
- Akiyoshi Saitoh
- Department of Pathophysiology & Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 4-41, Ebara 2-chome, Shinagawa-ku, Tokyo, 142-8501, Japan
| | | | | | | |
Collapse
|
5
|
Stone LS, Vulchanova L. The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Adv Drug Deliv Rev 2003; 55:1081-112. [PMID: 12935946 DOI: 10.1016/s0169-409x(03)00105-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
As the genomic revolution continues to evolve, there is an increasing demand for efficient and reliable tools for functional characterization of individual gene products. Antisense oligonucleotide-mediated knockdown has been used successfully as a functional genomics tool in animal models of pain and analgesia yet skepticism regarding the validity and utility of antisense technology remains. Contributing to this uncertainty are the lack of systematic studies exploring antisense oligonucleotide use in vivo and the many technical and methodological challenges intrinsic to the method. This article reviews the contributions of antisense oligonucleotide-based studies to the field of pain and analgesia and the general principles of antisense technology. A special emphasis is placed on technical issues surrounding the successful application of antisense oligonucleotides in vivo, including sequence selection, antisense oligonucleotide chemistry, DNA controls, route of administration, uptake, dose-dependence, time-course and adequate evaluation of knockdown.
Collapse
Affiliation(s)
- Laura S Stone
- Department of Neuroscience, University of Minnesota, 6-125 Jackson Hall, 321 Church Street S.E., Minneapolis, MN 55455, USA.
| | | |
Collapse
|
6
|
Wang H, Wessendorf MW. Mu- and delta-opioid receptor mRNAs are expressed in periaqueductal gray neurons projecting to the rostral ventromedial medulla. Neuroscience 2002; 109:619-34. [PMID: 11823071 DOI: 10.1016/s0306-4522(01)00328-1] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Opioid antinociception appears to be mediated at least in part by a pathway that projects from the periaqueductal gray (PAG) to the rostral ventromedial medulla (RVM), but the relationship between opioid receptors and PAG-RVM projection neurons is unclear. Previous electrophysiological studies have suggested that opioids act directly on some PAG neurons projecting to the RVM. However, immunoreactivity for neither the cloned mu-opioid receptor (MOR1) nor the cloned delta-opioid receptor (DOR1) has been observed in PAG cells retrogradely labeled from the RVM. In the present study, we examined the expression of DOR1 and MOR1 mRNAs in PAG neurons projecting to RVM using quantitative in situ hybridization and retrograde tract-tracing. Mesencephalic neurons were labeled in three male Sprague-Dawley rats by microinjection of Fluoro-Gold into the RVM. Five micrometer cryostat sections were cut and in situ hybridization was performed using full-length cRNA probes labeled with 35S-UTP. Retrogradely labeled neurons that were also labeled for MOR1 or DOR1 mRNA were observed in the dorsomedial, lateral, and ventrolateral portions of the PAG. Quantification was performed in the dorsomedial and ventrolateral PAG using the physical disector. We found that of 219 retrogradely labeled neurons, 50 +/- 14% expressed DOR1 mRNA. In a second set of 120 Fluoro-Gold-labeled neurons, 27 +/- 8% expressed MOR1 mRNA. Significantly more PAG-RVM projection neurons were labeled for MOR1 mRNA in the ventrolateral subregion of the PAG than in the dorsomedial subregion. However, no significant difference was observed in the proportions of retrogradely labeled neurons labeled for DOR1 mRNA in the ventrolateral subregion compared to the dorsomedial subregion. We conclude that opioids are likely to exert direct effects on PAG-RVM projection neurons through both delta- and mu-opioid receptors. In addition, direct effects on PAG-RVM projection neurons from activation of MOR1 appear more likely to be exerted in the ventrolateral PAG than in the dorsomedial PAG.
Collapse
Affiliation(s)
- H Wang
- Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
| | | |
Collapse
|
7
|
Stefano GB, Ottaviani E. The biochemical substrate of nitric oxide signaling is present in primitive non-cognitive organisms. Brain Res 2002; 924:82-9. [PMID: 11743998 DOI: 10.1016/s0006-8993(01)03227-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Nitric oxide has been shown to have diverse actions in the mammalian nervous, immune and vascular systems. These include antimicrobial and antiviral activities as well as the modulation of cell adherence. In the nervous system, nitric oxide modulates neurotransmitter release, neurosecretion and behavioral activities such as feeding. In the present review, we discuss the finding that invertebrate organisms also contain nitric oxide and that they appear to use this multidimensional molecule in a similar manner as noted for mammals. Therefore, nitric oxide signaling appears to have emerged first in these primitive non-cognitive organisms. We conclude that basal nitric oxide functioning was established in these organisms and that this molecule was later employed in man, including its involvement in cognitive neural processes.
Collapse
Affiliation(s)
- George B Stefano
- Neuroscience Research Institute, State University of New York College at Old Westbury, Old Westbury, NY 11568-0210, USA.
| | | |
Collapse
|
8
|
Pol O, Valle L, Puig MM. Antisense oligodeoxynucleotides to mu- and delta-opioid receptor mRNA block the enhanced effects of opioids during intestinal inflammation. Eur J Pharmacol 2001; 428:127-36. [PMID: 11779029 DOI: 10.1016/s0014-2999(01)01281-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Intestinal inflammation enhances the inhibitory effects of mu- and delta-opioids in the gut, possibly related to an increased receptor expression. We evaluated the effects of opioids after intraperitoneal administration of antisense oligodeoxynucleotides to mu- and/or delta-opioid receptor mRNA. Inflammation was induced in mice by intragastric administration of croton oil; gastrointestinal transit was assessed with charcoal and permeability with [51Cr]etylenediaminetetraacetate ([51Cr]EDTA). Baseline values were unaltered after antisense oligodeoxynucleotides. In controls, antisense oligodeoxynucleotides to mu-opioid receptor mRNA decreased the antitransit effects of morphine (27%) and [N-MePhe3D-Pro4]morphiceptin (PL017) (26%), and the reduction was significantly greater during inflammation (50% and 47%). A similar effect was observed on permeability (control: 41-21% decrease; inflamed: 66-45%). In both assays, antisense oligodeoxynucleotides to delta-opioid receptor mRNA also reduced the effects of [D-Pen2,5]enkephalin (DPDPE) in a higher percentage during inflammation (43-32% controls, 60-49% inflamed). We show that antisense oligodeoxynucleotides to mu- and/or delta-opioid receptor mRNA are efficiently blocking the intestinal effects of opioids during inflammation, suggesting that an increased transcription of these receptors in the gut mediates the enhanced effects of opioids during inflammation.
Collapse
MESH Headings
- Animals
- Croton Oil
- Endorphins/pharmacology
- Enkephalin, D-Penicillamine (2,5)-/pharmacology
- Enteritis/chemically induced
- Enteritis/physiopathology
- Gastrointestinal Transit/drug effects
- Intestinal Absorption/drug effects
- Irritants
- Male
- Mice
- Morphine/pharmacology
- Narcotic Antagonists/pharmacology
- Narcotics/pharmacology
- Oligonucleotides, Antisense/pharmacology
- RNA, Messenger/biosynthesis
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/biosynthesis
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/biosynthesis
- Receptors, Opioid, mu/genetics
Collapse
Affiliation(s)
- O Pol
- Anesthesiology Research Unit, IMIM, Department of Anesthesiology, Hospital Universitario del Mar, Universidad Autónoma de Barcelona, Spain
| | | | | |
Collapse
|
9
|
Abstract
A large body of evidence suggests an important role of delta-opioid receptor agonists in antinociception at the level of the spinal cord. Our study was undertaken to analyse the spinal antinociceptive and antiallodynic effects of delta(1)- and delta(2)-opioid receptor agonists and antagonist after their acute and chronic intrathecal administration in a neuropathic pain model in the rat. In rats with a crushed sciatic nerve, the delta(1)-opioid receptor agonist [D-Pen(2), D-Pen(5)]enkephalin (DPDPE, 5-25 microg i.t.) and the delta(2)-opioid receptor agonist deltorphin II (1.5-25 microg i.t.) dose dependently antagonized the cold-water allodynia which developed after sciatic nerve injury. These effects of DPDPE were antagonized by 7-benzylidenenaltrexon (BNTX, 1 microg i.t.) while the effects of deltorphin II were antagonized by 5'naltrindole izotiocyanate (5'NTII, 25 microg i.t.). Both agonists had a dose-dependent, statistically significant effect on the tail-flick latency in two tests, with focused light and cold water. Chronic administration of DPDPE (25 microg i.t.) and deltorphin II (15 microg i.t.) resulted in significant prolongation of the reaction time determined on days 2, 4 and 6 post-injury. In conclusion, our results show an antiallodynic and antinociceptive action of DPDPE and deltorphin II at the spinal cord level, which suggests that both delta-opioid receptor subtypes play a similar role in neuropathic pain. This indicates that not only delta(1)- but also delta(2)-opioid receptor agonists can be regarded as potential drugs for the therapy of neuropathic pain.
Collapse
MESH Headings
- Analgesics, Opioid/pharmacology
- Animals
- Behavior, Animal/drug effects
- Benzylidene Compounds/pharmacology
- Dose-Response Relationship, Drug
- Enkephalin, D-Penicillamine (2,5)-/pharmacology
- Isothiocyanates/pharmacology
- Male
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Neuralgia/physiopathology
- Neuralgia/prevention & control
- Oligopeptides/pharmacology
- Pain Measurement
- Protein Isoforms/physiology
- Rats
- Rats, Wistar
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/physiology
- Sciatic Nerve/injuries
- Time Factors
Collapse
Affiliation(s)
- J Mika
- Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Cracow, Poland
| | | | | |
Collapse
|
10
|
Abstract
In 1980 the skin of certain frogs belonging to the genus Phyllomedusinae was found to contain two new peptides that proved to be selective mu-opioid agonists, and named dermorphins. Since 1987 deltorphins, a family of highly selective delta-opioid peptides were identified either by cloning of the cDNA from frog skins or isolation of the peptides. The distinctive feature of opioid peptides is the presence of a naturally occurring D-enantiomer at the second position in their common N-terminal sequence, Tyr-D-Xaa-Phe. The discovery of the amphibian opiate peptides, provided new insights into the functional role of the mu- and delta-opiate systems. It also provided models for novel analgesics with enhanced therapeutic benefits and reduced toxicity.
Collapse
Affiliation(s)
- L Negri
- Department of Human Physiology and Pharmacology, University "La Sapienza," P.le Aldo Moro, 5, I-00185, Rome, Italy.
| | | | | |
Collapse
|
11
|
Negri L, Broccardo M, Lattanzi R, Melchiorri P. Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats. Br J Pharmacol 1999; 128:1554-60. [PMID: 10602336 PMCID: PMC1571778 DOI: 10.1038/sj.bjp.0702931] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. To reduce the density of delta-opioid receptor protein, five antisense phosphorothioate oligodeoxynucleotides (aODN), targeting the three exons of rat delta-opioid receptor mRNA (DOR), were injected twice daily for 4 days or continuously infused for 7 days into brain lateral ventricles (i.c.v.) of Sprague-Dawley rats. Rats acting as controls were infused or injected with a mismatch sequence (mODN) of each aODN. The density of opioid receptors in rat brain membranes was measured by saturation binding experiments using selective ligands for delta, mu and kappa opioid receptors. 2. aODNs injected twice a day for 4 days left rat brain delta-opioid receptor density unchanged. The ODN targeting the DOR nucleotide sequence 280 - 299 (aODN280 - 299, exon 2), decreased brain delta-opioid receptor density significantly more than aODNs targeting exon 1 (aODN239 - 258), exon 2 (aODN361 - 380), or exon 3 (aODN741 - 760) (to 52% vs 79, 72, and 68%). None of the aODNs to the DOR changed the brain density of mu- or k-opioid receptors. 3. When in a novel environment (but not when kept in their home cages), the locomotor activity of aODN280 - 299 treated rats was significantly lower than that of saline or mODN treated rats. The delta-opioid agonist SNC80 (5 mg kg-1, s.c.) significantly and potently stimulated locomotion and delayed colonic propulsion in saline- and mODN-infused rats, but left motor behaviour and colonic transit of delta-knockdown rats unchanged. 4. The baseline nociceptive threshold and the antinociceptive response to morphine were unchanged in delta-knockdown rats.
Collapse
MESH Headings
- Analgesics, Opioid/pharmacology
- Animals
- Behavior, Animal/drug effects
- Benzamides/pharmacology
- Brain/drug effects
- Brain/metabolism
- Colon/drug effects
- Colon/physiology
- Gastrointestinal Transit/drug effects
- Gastrointestinal Transit/physiology
- Injections, Intraventricular
- Male
- Morphine/pharmacology
- Motor Activity/drug effects
- Motor Activity/physiology
- Nociceptors/drug effects
- Nociceptors/physiology
- Oligodeoxyribonucleotides, Antisense/genetics
- Oligodeoxyribonucleotides, Antisense/pharmacology
- Piperazines/pharmacology
- RNA, Messenger/drug effects
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, delta/biosynthesis
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/metabolism
- Thionucleotides/genetics
- Thionucleotides/pharmacology
Collapse
Affiliation(s)
- L Negri
- Institute of Medical Pharmacology, University La Sapienza, Piazza A. Moro, 5 Rome, Italy.
| | | | | | | |
Collapse
|
12
|
Garzón J, de Antonio I, Sánchez-Blázquez P. In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods Enzymol 1999; 314:3-20. [PMID: 10565001 DOI: 10.1016/s0076-6879(99)14091-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The work in our laboratory has been designed to characterize the transducer mechanisms coupled to neurotransmitter receptors in the plasma membrane. Particular attention has been paid to the physiological/pharmacological effects mediated by the opioid system. Antisense oligodeoxynucleotides have proved useful in correlating opioid receptor clones with those defined pharmacologically. The involvement of the cloned opioid receptors mu, delta, and kappa in analgesia has been determined by means of in vivo injection of ODNs directed to the receptor mRNAs. Using this strategy the classes of G-transducer proteins regulated by each type/subtype of opioid receptor in the promotion of antinociception have also been characterized. After displaying different patterns of binding to their receptors, opioids trigger a variety of intracellular signals. The physiological implications and therapeutic potential of these findings merit consideration.
Collapse
Affiliation(s)
- J Garzón
- Department of Neuropathology, Cajal Institute, Madrid, Spain
| | | | | |
Collapse
|
13
|
Hutcheson DM, Sánchez-Blazquez P, Rodriguez-Diaz M, Garzon J, Schmidhammer H, Borsodi A, Roques BP, Maldonado R. Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception. Eur J Pharmacol 1999; 383:29-37. [PMID: 10556678 DOI: 10.1016/s0014-2999(99)00611-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Evidence suggests that the antinociceptive effects of selective delta-opioid receptor agonists may involve an activation of the mu-receptor in some experimental conditions. The aim of this study was to clarify the receptors involved in the antinociceptive responses of the selective and systemically active delta-opioid receptor agonist Tyr-D-Ser-(O-tert-butyl)-Gly-Phe-Leu-Thr-(O-tert-butyl) (BUBU). The antinociception induced by systemic (i.v.) or central (i.c.v.) administration of BUBU was measured in the hot plate (jumping and paw lick latencies) and tail immersion tests in mice. In both tests, the responses were more intense when BUBU was administered by central route. The pre-treatment with the mu-opioid receptor antagonist cyprodime blocked the effects induced by central BUBU in the hot plate and tail immersion tests. The delta-opioid receptor antagonist naltrindole had no effect on BUBU-induced antinociception in the hot plate but decreased BUBU responses in the tail immersion test. Further evidence for this dual receptor action of BUBU was demonstrated by using antisense oligodeoxynucleotides. Thus, a reduction in central BUBU-induced antinociception was observed in the tail immersion test after the administration of antisense probes that selectively blocked the expression of mu- or delta-opioid receptors. These findings clearly indicate using a dual pharmacological and molecular approach that BUBU mediates its antinociceptive effects via activation of both mu- and delta-opioid receptors.
Collapse
MESH Headings
- Analgesics/administration & dosage
- Analgesics/pharmacology
- Animals
- Male
- Mice
- Morphinans/pharmacology
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Oligonucleotides, Antisense/chemical synthesis
- Oligonucleotides, Antisense/pharmacology
- Oligopeptides/administration & dosage
- Oligopeptides/pharmacology
- Pain Measurement
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/physiology
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/physiology
Collapse
Affiliation(s)
- D M Hutcheson
- Département de Pharmacochimie Moléculaire et Structurale, INSERM U266 CNRS UMR 8600, UFR des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, 75270, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Becker C, Hamon M, Cesselin F, Benoliel JJ. Delta(2)-opioid receptor mediation of morphine-induced CCK release in the frontal cortex of the freely moving rat. Synapse 1999; 34:47-54. [PMID: 10459171 DOI: 10.1002/(sici)1098-2396(199910)34:1<47::aid-syn6>3.0.co;2-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Numerous pharmacological data have been accumulated in support of the existence of physiological interactions between cholecystokinin (CCK) and opioids in the central nervous system. With the aim of further characterizing these interactions, an in vivo microdialysis approach was used to directly assess the possible influence of opioids on the extracellular levels of CCK-like material (CCKLM) in the frontal cortex of the awake, freely moving rat. Systemic administration of a high dose of morphine (10 mg/kg i.p.) produced a marked increase (up to +200%) of cortical CCKLM outflow, and this effect could be completely prevented by systemic (1.5 mg/kg i.p.) as well as intracortical (10 microM) administration of the opioid receptor antagonist naloxone. The opioid receptors activated by morphine appeared to be of the delta type because the intracortical infusion of naltrindole (10 microM) also prevented the effect of morphine, whereas CTOP (10 microM), a selective mu-opioid receptor antagonist, and nor-binaltorphimine (10 microM), a selective kappa-opioid receptor antagonist, were inactive. In addition, naltriben (10 microM), which acts selectively at the delta(2) subtype, also abolished the stimulatory effect of morphine on cortical CCKLM outflow, whereas 7-benzylidenenaltrexone (10 microM), a selective delta(1)-opioid receptor antagonist (10 microM), did not alter the morphine effect. Conversely, the direct stimulation of cortical delta(2)-opioid receptors by local infusion of [D-Ala(2)] deltorphin II mimicked the stimulatory effect of systemic morphine on CCKLM outflow. These data indicate that delta(2)-opioid receptors play a key role in opioid-CCK interactions in the rat frontal cortex.
Collapse
Affiliation(s)
- C Becker
- INSERM U. 288, NeuroPsychoPharmacologie Moléculaire, Cellulaire et Fonctionnelle, Paris, France.
| | | | | | | |
Collapse
|
15
|
Abstract
To address the neurochemistry of the mechanisms that underlie the development of acute and persistent pain, our laboratory has been studying mice with deletions of gene products that have been implicated in nociceptive processing. We have recently raised mice with a deletion of the preprotachykinin-A gene, which encodes the peptides substance P (SP) and neurokinin A (NKA). These studies have identified a specific behavioral phenotype in which the animals do not detect a window of "pain" intensities; this window cuts across thermal, mechanical, and chemical modalities. The lowered thermal and mechanical withdrawal thresholds that are produced by tissue or nerve injury, however, were still present in the mutant mice. Thus, the behavioral manifestations of threshold changes in nociceptive processing in the setting of injury do not appear to require SP or NKA. To identify relevant neurochemical factors downstream of the primary afferent, we are also studying the dorsal horn second messenger systems that underlie the development of tissue and nerve injury-induced persistent pain states. We have recently implicated the gamma isoform of protein kinase C (PKCgamma) in the development of nerve injury-induced neuropathic pain. Acute pain processing, by contrast, is intact in the PKCgamma-null mice. Taken together, these studies emphasize that there is a distinct neurochemistry of acute and persistent pain. Persistent pain should be considered a disease state of the nervous system, not merely a prolonged acute pain symptom of some other disease conditions.
Collapse
Affiliation(s)
- A I Basbaum
- Departments of Anatomy and Physiology and W. M. Keck Foundation Center for Integrative Neuroscience, University of California, San Francisco, CA 94143, USA.
| |
Collapse
|
16
|
Pol O, Valle L, Sánchez-Blázquez P, Garzón J, Puig MM. Antibodies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively block the effects of mu-opioid agonists on intestinal transit and permeability in mice. Br J Pharmacol 1999; 127:397-404. [PMID: 10385239 PMCID: PMC1566040 DOI: 10.1038/sj.bjp.0702570] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. We have studied the effects of mu and delta opioids on intestinal function (permeability, PER; gastrointestinal transit, GIT), and their antagonism after the intracerebroventricular (i.c.v.) administration of specific antibodies (ABs) or antisense oligodeoxynucleotides (ODN) to mu-receptors (OR). Central versus peripheral site/s of action of subcutaneous (s.c.) mu-opioids, were also assessed. 2. Male Swiss CD-1 mice were used. GIT was measured with charcoal and PER by the passage of 51Cr-EDTA from blood to lumen. 3. Morphine and fentanyl (i.c.v. and s.c.) inhibited GIT and PER in a dose-related manner; they were more potent by i.c.v. route, both on GIT and PER (70 and 17 times for morphine and fentanyl). They also had a greater effect on GIT than PER (4.3 and 1.6 times). DPDPE had a lower potency than mu-agonists in all experiments, and no dose-response could be obtained after s.c. administration on GIT. 4. Pretreatment with i.c.v. ABs (24 h) or antisense ODN (5 days), decreased the effects (GIT and PER) of i.c.v. morphine and fentanyl, while those of DPDPE remained unchanged. The ABs did not alter the peripheral effects of mu-opioids. 5. The results show that (i.c.v. or s.c.) mu opioids produce dose-related inhibitions of PER and GIT, being more potent by the i.c.v. route. Delta-opioids had a greater effect on PER than GIT, while the opposite occurred for mu-agonists. Pretreatment with ABs or ODN to mu-OR, blocked the central effects of mu (but not delta) agonists on GIT and PER.
Collapse
MESH Headings
- Animals
- Antibodies, Blocking/pharmacology
- Dose-Response Relationship, Drug
- Endorphins/pharmacology
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Fentanyl/antagonists & inhibitors
- Fentanyl/pharmacology
- Gastrointestinal Transit/drug effects
- Injections, Intraventricular
- Intestinal Absorption/drug effects
- Male
- Mice
- Morphine/antagonists & inhibitors
- Morphine/pharmacology
- Narcotic Antagonists/pharmacology
- Oligodeoxyribonucleotides, Antisense/pharmacology
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/immunology
Collapse
Affiliation(s)
- Olga Pol
- Department of Anesthesiology, Hospital Universitario del Mar, IMIM, Passeig, Marítim 22, 08003, Barcelona, Spain
| | - Lluís Valle
- Department of Anesthesiology, Hospital Universitario del Mar, IMIM, Passeig, Marítim 22, 08003, Barcelona, Spain
| | - Pilar Sánchez-Blázquez
- Department of Neuropharmacology, Instituto de Neurobiología Santiago Ramón y Cajal, CSIC, Madrid, Spain
| | - Javier Garzón
- Department of Neuropharmacology, Instituto de Neurobiología Santiago Ramón y Cajal, CSIC, Madrid, Spain
| | - Margarita M Puig
- Department of Anesthesiology, Hospital Universitario del Mar, IMIM, Passeig, Marítim 22, 08003, Barcelona, Spain
- Author for correspondence:
| |
Collapse
|
17
|
Szklarczyk AW, Kaczmarek L. Brain as a unique antisense environment. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT 1999; 9:105-16. [PMID: 10192296 DOI: 10.1089/oli.1.1999.9.105] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
During the last few years, antisense oligodeoxyribonucleotides (asODN) have become a commonly used tool for blocking of gene expression in the mammalian central nervous system. Successful gene inhibition has been reported for such diverse targets as those encoding neurotransmitter receptors, neuropeptides, trophic factors, transcription factors, cytokines, transporters, ion channels, and others. This review presents a discussion of recent studies on ODN in the brain, with a focus on specific approaches taken by the researchers in this field and especially on peculiar features of this organ as a milieu for asODN action. It is concluded that from the presented literature survey no coherent view on how to rationally design ODN for brain studies has emerged.
Collapse
Affiliation(s)
- A W Szklarczyk
- Department of Molecular and Cellular Neurobiology, Nencki Institute, Warsaw, Poland
| | | |
Collapse
|
18
|
Abstract
The deltorphins are a class of highly selective delta-opioid heptapeptides from the skin of the Amazonian frogs Phyllomedusa sauvagei and P. bicolor. The first of these fascinating peptides came to light in 1987 by cloning of the cDNA of from frog skins, while the other members of this family were identified either by cDNA or isolation of the peptides. The distinctive feature of deltorphins is the presence of a naturally occurring D-enantiomer at the second position in their common N-terminal sequence, Tyr-D-Xaa-Phe, comparable to dermorphin, which is the prototype of a group of mu-selective opioids from the same source. The D-amino acid and the anionic residues, either Glu or Asp, as well as their unique amino acid compositions are responsible for the remarkable biostability, high delta-receptor affinity, bioactivity and peptide conformation. This review summarizes a decade of research from many laboratories that defined which residues and substituents in the deltorphins interact with the delta-receptor and characterized pharmacological and physiological activities in vitro and in vivo. It begins with a historical description of the topic and presents general schema for the synthesis of peptide analogues of deltorphins A, B and C as a means to document the methods employed in producing a myriad of analogues. Structure activity studies of the peptides and their pharmacological activities in vitro are detailed in abundantly tabulated data. A brief compendium of the current level of knowledge of the delta-receptor assists the reader to appreciate the rationale for the design of these analogues. Discussion of the conformation of these peptides addresses how structure leads to further hypotheses regarding ligand receptor interaction. The review ends with a broad discussion of the potential applications of these peptides in clinical and therapeutic settings.
Collapse
Affiliation(s)
- L H Lazarus
- Peptide Neurochemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | | |
Collapse
|
19
|
Kest B, Lee CE, Jenab S, Kao B, Inturrisi CE. Chronic naltrexone differentially affects supraspinal delta-opioid receptor-mediated antinociception. Eur J Pharmacol 1998; 345:47-53. [PMID: 9593593 DOI: 10.1016/s0014-2999(97)01584-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The effects of chronic treatment with naltrexone, an opioid receptor antagonist, on delta1- and delta2-opioid receptor agonist-induced antinociception and ligand binding were investigated in mice. Antinociception by intracerebroventricular (i.c.v.) [D-Pen2,5]enkephalin (DPDPE) and [D-Ala2]deltorphin II, agonists selective for delta1- and delta2-opioid receptors, respectively, was blocked following subcutaneous (s.c.) implantation of a naltrexone pellet (7.5 mg) for 7 days. Removal of the naltrexone pellet was followed 24 h later by a decrease of 7.5-fold in the ED50 value of [D-Ala2]deltorphin II, but not that of DPDPE. In a whole brain homogenate the binding of [3H][D-Ala2]deltorphin II was increased twice as much as that of [3H]DPDPE. Chronic naltrexone treatment also produced an 8.6-fold decrease in the ED50 value of i.c.v. administered morphine. The increase in morphine potency was reversed to a control (placebo-treated mice) value by the selective delta2-opioid receptor antagonist, naltriben (25 pmol, i.c.v.). Thus, chronic naltrexone selectively increases delta2-opioid receptor-mediated antinociception, supporting the existence of delta opioid receptor subtypes with distinct adaptive characteristics. The data also indicate that delta2-opioid receptors are critically involved in the expression of morphine supersensitivity.
Collapse
Affiliation(s)
- B Kest
- Department of Pharmacology, LC-524, Cornell University Medical College, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
20
|
Xu H, Lu YF, Partilla JS, Pinto J, Calderon SN, Matecka D, Rice KC, Lai J, Porreca F, Ananthan S, Rothman RB. Opioid peptide receptor studies. 8. One of the mouse brain deltaNCX binding sites is similar to the cloned mouse opioid delta receptor: further evidence for heterogeneity of delta opioid receptors. Peptides 1998; 19:343-50. [PMID: 9493867 DOI: 10.1016/s0196-9781(97)00294-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Quantitative ligand binding studies resolved two subtypes of the delta opioid receptor, termed delta(ncx1) and delta(ncx2), in mouse brain membranes depleted of mu receptors by pretreatment with the irreversible ligand, BIT. The purpose of the present study was to compare the binding parameters, ligand-selectivity profile and pharmacological properties of the cloned mouse delta receptor (MDOR) stably expressed in a cell line to the delta(ncx) binding sites of mouse brain. [3H][D-Ala2,D-Leu5]enkephalin labeled a single binding site in membranes prepared from MDOR cells under several different assay conditions including BIT-pretreatment. The MDOR had high affinity for delta agonists and antagonists. [3H][D-Ala2,D-Leu5]enkephalin labeled two binding sites in mouse brain membranes depleted of mu receptors by pretreatment with BIT: the delta(ncx1) site (high affinity for DPDPE and deltorphin) and the delta(ncx2) site (low affinity for DPDPE and deltorphin). Some agents were moderately selective for the delta(ncx2) site: [pCl]DPDPE (10.9-fold), JP41 (5.9-fold) and JP45 (3.8-fold). The Ki values of 12 opioids at the mouse MDOR were determined. These values were highly correlated with their values at the delta(ncx1) site but not the delta(ncx2) site. These data suggest that the delta(ncx2) site may be distinct from the cloned delta opioid receptor.
Collapse
MESH Headings
- Animals
- Binding Sites
- Brain/metabolism
- Cell Line
- Cell Membrane/metabolism
- Cloning, Molecular
- Enkephalin, Leucine-2-Alanine/analogs & derivatives
- Enkephalin, Leucine-2-Alanine/metabolism
- Enkephalin, Leucine-2-Alanine/pharmacology
- In Vitro Techniques
- Kinetics
- Ligands
- Mice
- Receptors, Opioid, delta/classification
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/metabolism
Collapse
Affiliation(s)
- H Xu
- Clinical Psychopharmacology Section, Division of Intramural Research, NIDA, NIH, Baltimore, MD 21224, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ni Q, Xu H, Partilla JS, Rice KC, Matecka D, Calderon SN, Porreca F, Lai J, Schmidhammer H, Krassnig R, Rothman RB. Opioid peptide receptor studies. 9. Identification of a novel non-mu- non-delta-like opioid peptide binding site in rat brain. Peptides 1998; 19:1079-90. [PMID: 9700759 DOI: 10.1016/s0196-9781(98)00046-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Quantitative binding studies resolved two high-affinity [3H][D-Ala2,D-Leu5]enkephalin binding sites in rat brain membranes depleted of mu binding sites by pretreatment with the irreversible agent BIT. The two binding sites had lower (delta ncx-2, Ki = 96.6 nM) and higher (delta ncx-1, Ki = 1.55 nM) affinity for DPDPE. The ligand-selectivity profile of the delta ncx-1 site was that of a classic delta binding site. The ligand-selectivity profile of the delta ncx-2 site was neither mu- or delta-like. The Ki values of selected agents for the delta ncx-2 site were: [pCl]DPDPE (3.9 nM), DPLPE (140 nM), and DAMGO (2.6 nM). Under these assay conditions, [3H][D-Ala2,D-Leu5]enkephalin binding to the cells expressing the cloned mu receptor is very low and pretreatment of cell membranes with BIT almost completely inhibits [3H]DAMGO and [3H][D-Ala2,D-Leu5]enkephalin binding. Intracerebroventricular administration of antisense DNA to the cloned delta receptor selectively decreased [3H][D-Ala2,D-Leu5]enkephalin binding to the delta ncx-1 site. Administration of buprenorphine to rats 24 h prior to preparation of membranes differentially affected mu, delta ncx-1, and delta ncx-2 binding sites. Viewed collectively, these studies have identified a novel non-mu- non-delta-like binding site in rat brain.
Collapse
MESH Headings
- Analgesics, Opioid/metabolism
- Animals
- Binding Sites
- Brain/metabolism
- Brain Chemistry
- Buprenorphine/metabolism
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalin, Leucine-2-Alanine/metabolism
- Enkephalins/metabolism
- Ligands
- Oligonucleotides, Antisense/metabolism
- Protein Binding
- Rats
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/genetics
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/genetics
- Receptors, Opioid, mu/metabolism
Collapse
Affiliation(s)
- Q Ni
- Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, MD 21224, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Lee CE, Kest B, Jenab S, Inturrisi CE. Effect of supraspinal antisense oligodeoxynucleotide treatment on delta-opioid receptor mRNA levels in mice. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1997; 48:17-22. [PMID: 9379841 DOI: 10.1016/s0169-328x(97)00054-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Studies in vivo demonstrate that antisense oligodeoxynucleotide (ODN) treatment specifically reduces the functions mediated by numerous central nervous system (CNS) receptors, including opioid receptors. However, the effects of antisense ODN on the opioid receptor mRNA target, itself are rarely examined. In the present study, the effect of supraspinal antisense ODN administration on delta-opioid receptor (DOR) mRNA levels in selected CNS regions, was investigated in mice. ODN targeting a 20-nucleotide sequence of the DOR mRNA transcript was administered by intracerebroventricular (i.c.v.) injection twice daily for 3 days. First, to confirm that antisense ODN treatment decreases DOR function in this system, antinociception produced by DOR-selective agonist [D-Ala2]deltorphin II was assessed on day 4. A 2-fold reduction in [D-Ala2]deltorphin II potency was revealed in antisense ODN-treated mice compared to mice receiving control treatments. DOR mRNA levels in selected CNS regions which either mediate antinociception; medial thalamus (MThal), periaqueductal gray (PAG), frontal cortex (FCtx) and spinal cord (SpC) or exhibit relatively high levels of DOR mRNA; nucleus accumbens (Acb) and caudate-putamen (CPu) were then quantitated by solution hybridization. Levels of DOR mRNA in antisense ODN-treated mice were not different from levels in mice treated with saline vehicle, which ranged from 0.07 pg/microg total RNA in MThal and PAG to 0.26 pg/microg total RNA in CPu. These results are both consistent with previous reports that antisense oligodeoxynucleotide (ODN) treatment down-regulates DOR protein in vivo and indicate that this down-regulation is not associated with altered DOR mRNA levels.
Collapse
Affiliation(s)
- C E Lee
- Department of Pharmacology, Cornell University Medical College, New York, NY 10021, USA
| | | | | | | |
Collapse
|
23
|
Rossi GC, Su W, Leventhal L, Su H, Pasternak GW. Antisense mapping DOR-1 in mice: further support for delta receptor subtypes. Brain Res 1997; 753:176-9. [PMID: 9125445 DOI: 10.1016/s0006-8993(97)00081-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In contrast to the pharmacological studies implicating delta-opioid receptor subtypes, cloning studies have identified only a single cDNA encoding a delta receptor, DOR-1. Antisense studies have established the importance of DOR-1 in delta analgesia in mice. Antisense mapping extends this approach to include oligodeoxynucleotides which are targeted against each of the exons of the gene. Five different antisense oligodeoxynucleotides based upon the three DOR-1 exons all block both spinal and supraspinal analgesic actions of the delta2 ligand [D-Ala2,Glu4]deltorphin, consistent with the suggestion that DOR-1 encodes the delta2 receptor. At the spinal level, [D-Pen2,D-Pen5]enkephalin (DPDPE) acts also acts through delta2 receptors and all the antisense probes block spinal DPDPE analgesia. However, supraspinally only the two antisense probes targeting exon 3 block DPDPE analgesia. The remaining three antisense probes based upon exons 1 and 2 are inactive. Thus, the delta receptors responsible for spinal and supraspinal DPDPE analgesia can be discriminated at the molecular level by antisense mapping.
Collapse
MESH Headings
- Analgesia
- Animals
- Cloning, Molecular
- DNA, Antisense/genetics
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Exons
- Male
- Mice
- Mice, Inbred Strains
- Oligonucleotides, Antisense/genetics
- Oligopeptides/pharmacology
- Peptide Mapping/methods
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/genetics
Collapse
Affiliation(s)
- G C Rossi
- Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
24
|
Negri L, Severini C, Lattanzi R, Potenza RL, Melchiorri P. Postnatal development of delta-opioid receptor subtypes in mice. Br J Pharmacol 1997; 120:989-94. [PMID: 9134207 PMCID: PMC1564557 DOI: 10.1038/sj.bjp.0700990] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
1. The density and affinity of binding sites for the delta-selective opioid ligands [3H]-[D-Ala2, Asp4]deltorphin (DELT-I), [3H]-[D-Ala2Glu4]-deltorphin (DELT-II), [3H]-[D-Pen2,D-Pen5]enkephalin (DPDPE), and [3H]-naltrindole (NTI) were determined in whole brain from 10, 15, 25 and 60 day-old C57BL mice. 2. At all ages, the analyses of the homologous displacement curves, gave best fits to single rather than to multiple site models. The binding capacity (Bmax) labelled by [3H]-NTI was about one half that labelled by [3H]-DELT-I, [3H]-DELT-II and [3H]-DPDPE. In 25 and 60 day-old mouse brain the DPDPE Bmax was 25% less than the deltorphin-II Bmax. 3. In saturation experiments, specific binding of [3H]-DELT-I on adult mouse brain homogenates was best fitted by a two-site model (34%, high affinity site, Kd = 1.08 nM and 66% low affinity sites, Kd = 39.9 nM). 4. DPDPE produced a biphasic inhibition of specific [3H]-DELTI-I binding, from 15 days of age onwards. The relative percentage of high and low affinity sites was 72% and 28% in 15 day-, 65% and 35% in 25 day- and 30% and 70% in 60 day-old mice. 5. In adult mouse brain labelled with [3H]-DELT-I, DELT-II recognized 71% of high-affinity and 29% of low-affinity sites DELT-I and DPDPE produced monophasic inhibition of specific [3H]-DELT-II binding to brain homogenates of adult mice. 6. These data suggest that a sub-population of delta-sites (probably the delta 2-subtype), recognized by DELT-I, with high affinity for DELT-II and low affinity for DPDPE develops from 25 days onward. 7. In electrically stimulated mouse vas deferens (MVD) the rank order of potency of the three delta-agonists was: DELT-I > DELT-II > DPDPE in 10 day-old mice: and DELT-I- DELT-II > DPDPE, from 25 days onward. During this time, the potency of DELT-II increased about 15 fold whereas the potency of DELT-I and DPDPE increased only 5 times. The higher efficacy of DELT-II could depend on receptor maturation towards the delta 2-subtype.
Collapse
Affiliation(s)
- L Negri
- Institute of Medical Pharmacology, University La Sapienza, Rome, Italy
| | | | | | | | | |
Collapse
|
25
|
Shah S, Duttaroy A, Chen BT, Carroll J, Yoburn BC. The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation. Brain Res Bull 1997; 42:479-84. [PMID: 9128924 DOI: 10.1016/s0361-9230(96)00375-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The present study examined the effect of in vivo antisense oligodeoxynucleotide treatment on naltrexone (NTX)-induced functional supersensitivity and mu-opioid receptor up-regulation in mice. On day 1 mice were implanted S.C. with a NTX or placebo pellet and injected I.T. and I.C.V. with dH2O or oligodeoxynucleotides. The oligodeoxynucleotides were designed so that they were either perfectly complementary to the first 18 bases of the coding region of mouse mu-opioid receptor mRNA, or had one (Mismatch-1) or four (Mismatch-4) mismatches. On days 3, 5, 7, and 9, mice were again injected I.T. and I.C.V. with dH2O or one of the oligodeoxynucleotides. After the final injections on day 9, placebo and NTX pellets were removed, and 24 h later mice were tested for morphine analgesia or sacrificed for saturation binding studies ([3H]DAMGO). Naltrexone increased the analgesic potency of morphine in dH2O treated mice by approximately 70%. In binding studies, NTX significantly increased density of brain (approximately 60%) and spinal cord (approximately 140%) mu-opioid receptors without affecting affinity. The mu-opioid antisense and the oligodeoxynucleotide with one mismatch (Mismatch-1) significantly reduced the potency of morphine by approximately twofold in placebo-treated mice. The oligodeoxynucleotide with four mismatches (Mismatch-4) did not significantly alter morphine potency. When placebo-treated mice were treated with either the antisense to the mouse mu-opioid receptor, Mismatch-4 or Mismatch-1 there were no significant changes in the density of mu-opioid receptors. Thus, mu-opioid antisense significantly reduced morphine potency without changing mu-opioid receptor density. When NTX and oligodeoxynucleotide treatments were combined, there was no change in NTX-induced supersensitivity and mu-opioid receptor upregulation. These data suggest that opioid antagonist-induced supersensitivity and upregulation of mu-opioid receptors does not involve changes in gene expression.
Collapse
Affiliation(s)
- S Shah
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439, USA
| | | | | | | | | |
Collapse
|
26
|
Crooke ST. Advances in understanding the pharmacological properties of antisense oligonucleotides. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1997; 40:1-49. [PMID: 9217922 DOI: 10.1016/s1054-3589(08)60136-2] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- S T Crooke
- Isis Pharmaceuticals, Inc., Carlsbad, California 92008, USA
| |
Collapse
|
27
|
Suzuki T, Tsuji M, Ikeda H, Misawa M, Narita M, Tseng LF. Antisense oligodeoxynucleotide to delta opioid receptors blocks cocaine-induced place preference in mice. Life Sci 1997; 60:PL 283-8. [PMID: 9150423 DOI: 10.1016/s0024-3205(97)00143-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The effect of intracerebroventricular (i.c.v.) treatment with antisense oligodeoxynucleotide (A-oligo) to delta opioid receptor mRNA on cocaine-induced place preference was examined in mice. Cocaine (10 mg/kg, s.c.) produced a significant place preference. I.c.v. treatment with A-oligo (0.001-1 microg/mouse) dose-dependently attenuated the cocaine (10 mg/kg, s.c.)-induced place preference, although mismatched oligodeoxynucleotide (1 microg/mouse, i.c.v.) was ineffective. In the present study, we found that the selective reduction in number and/or function of central delta opioid receptors by A-oligo suppresses the cocaine-induced place preference. These results suggest that the conditioned reward by cocaine may be partially mediated by central delta opioid receptors.
Collapse
MESH Headings
- Animals
- Behavior, Animal/drug effects
- Cocaine/antagonists & inhibitors
- Cocaine/pharmacology
- Conditioning, Classical/drug effects
- Injections, Intraventricular
- Male
- Mice
- Mice, Inbred Strains
- Narcotic Antagonists/pharmacology
- Narcotics/pharmacology
- Nociceptors/drug effects
- Oligonucleotides/pharmacology
- Oligonucleotides, Antisense/pharmacology
- RNA, Messenger/genetics
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/physiology
Collapse
Affiliation(s)
- T Suzuki
- Department of Pharmacology, School of Pharmacy, Hoshi University, Shinagawa-ku, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
28
|
Noble F, Fournie-Zaluski MC, Roques BP. Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity. Neuroscience 1996; 75:917-26. [PMID: 8951884 DOI: 10.1016/0306-4522(96)00323-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Using the mouse caudate-putamen, where delta-opioid receptor subtypes have been shown to regulate adenylyl cyclase activity, we show in this study that endogenous enkephalins inhibit enzyme activity through activation of delta 1- and delta 2-opioid receptors. Thus, naltriben or 7-benzylidenenaltrexone as well as the delta-selective antagonist naltrindole (mixed delta 1 and delta 2 antagonist) antagonized inhibition of adenylyl cyclase activity induced by methionine- or leucine-enkephalin, while the micro-antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) was without effect. Furthermore, we have previously shown that activation of delta-opioid receptors increases cholecystokinin release in the central nervous system, resulting in a potentiation of micro-opioid antinociceptive responses, and the respective role of delta 1- and delta 2-opioid receptors in this facilitatory effect has now been evaluated. Activation of delta 2-opioid receptors, either by endogenous enkephalins protected from catabolism by the complete enkephalin-degrading enzyme inhibitor N-((R,S)-2-benzyl-3((S)(2-amino-4-methyl-thio) butyldithio)-1-oxopropyl)-L-phenyl-alanine benzyl ester (RB 101), or by the delta 2-selective agonist Tyr-D-Ser(O-tert-butyl)-Gly-Phe-Leu-Thr(O-tert-butyl) (BUBU), potentiated micro-opioid antinociceptive responses in the hot-plate test in mice. This effect was antagonized by a selective cholecystokinin-A antagonist. Activation of delta 1-opioid receptors by endogenous opioid peptides decreased the micro-opioid responses. These results suggest that stimulation of delta 2-opioid receptors potentiates micro-opioid analgesia in the hot-plate test in mice through an increase in endogenous cholecystokinin release, while activation of delta 1-opioid receptors could decrease it. Thus, the pre-existing physiological balance between opioid and cholecystokinin systems seems to be modulated in opposite directions depending on whether delta 1- or delta 2-opioid receptors are selectively activated. This is the first demonstration that endogenous enkephalins, methionine- and leucine-enkephalin, are the natural ligands of delta-opioid receptor subtypes, and that delta 2-opioid receptor activation may facilitate the endogenous cholecystokinin-related modulation of micro-opioid analgesia, while the delta 1-opioid receptors may have an inhibitory role. These results could have important applications for the characterization of opioid delta 1 and delta 2 as subtypes or subsites and in pain alleviation.
Collapse
Affiliation(s)
- F Noble
- Department de Pharmacochimie Moléculaire et Structurale, INSERM U266, CNRS URA D 1500, Université René Descartes, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France
| | | | | |
Collapse
|
29
|
Wang HQ, Kampine JP, Tseng LF. Antisense oligodeoxynucleotide to a delta-opioid receptor messenger RNA selectively blocks the antinociception induced by intracerebroventricularly administered delta-, but not mu-, epsilon- or kappa-opioid receptor agonists in the mouse. Neuroscience 1996; 75:445-52. [PMID: 8931008 DOI: 10.1016/0306-4522(96)00309-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
An antisense oligodeoxynucleotide to delta-opioid receptor messenger RNA was utilized to block the expression of mouse delta-opioid receptors for antinociception. The antinociception was measured by the tail-flick test in male ICR mice. Pretreatment with delta-antisense oligodeoxynucleotide (163 pmol) given intracerebroventricularly twice a day for one to four days produced a time-dependent inhibition of the tail-flick response induced by intracerebroventricularly administered (D-Ala2)deltorphin II (12.8 nmol). The (D-Ala2)deltorphin II-induced antinociception was significantly attenuated after three to four days of the delta-antisense oligodeoxynucleotide treatment, remained attenuated for two days and gradually recovered to the control level in four to 10 days after cessation of the pretreatment with delta-antisense oligodeoxynucleotide. Pretreatment with delta-antisense oligodeoxynucleotide (163 pmol) twice a day for four days markedly attenuated the antinociception induced by intracerebroventricularly administered (D-Ala2)deltorphin II and, to a lesser extent, by D-Pen2-D-Pen5-enkephalin and morphine, but not by (D-Ala2-MePhe4-Gly(ol)5)enkephalin, beta-endorphin or U50,488H. Mismatched oligodeoxynucleotide (163 pmol) was ineffective against the antinociception induced by these opioids. Our results provide the evidence that the cloned delta-opioid receptor is related to the pharmacologically classified delta 2-opioid receptor, and the antinociception induced by (D-Ala2)deltorphin II and, at least in part, by D-Pen2-D-Pen5-enkephalin and morphine given intracerebroventricularly is mediated by the stimulation of delta 2-opioid receptors. However, delta 2-opioid receptors are not involved in the antinociception induced by beta-endorphin, (D-Ala2-MePhe4-Gly(ol)5)enkephalin or U50,488H given intracerebroventricularly.
Collapse
MESH Headings
- Animals
- Injections, Intraventricular
- Kinetics
- Male
- Mice
- Mice, Inbred ICR
- Oligonucleotides, Antisense/pharmacology
- Pain Measurement/drug effects
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- Receptors, Opioid/agonists
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/biosynthesis
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, mu/agonists
- Receptors, sigma/agonists
Collapse
Affiliation(s)
- H Q Wang
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226, USA
| | | | | |
Collapse
|
30
|
Lai J, Riedl M, Stone LS, Arvidsson U, Bilsky EJ, Wilcox GL, Elde R, Porreca F. Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated 'knock-down' of the mouse delta opioid receptor in vitro and in vivo. Neurosci Lett 1996; 213:205-8. [PMID: 8873150 DOI: 10.1016/0304-3940(96)12883-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have previously used antisense oligodeoxynucleotides (ODN) to the cloned delta opioid receptor (DOR) to inhibit the antinociceptive response to spinally administered delta opioid receptor selective agonists in mice. Here we have examined the effect of DOR antisense ODN treatment on the level of DOR expressed in NG 108-15 cells and the spinal cord, through immuno-fluorescence microscopy, to determine the efficiency and selectivity of the antisense ODN-mediated "knock-down' of the DOR in these tissues. Antisense ODN, but not mismatch control, treatment resulted in a significant reduction in DOR immunoreactivity (-ir) in NG 108-15 cells and spinal cord. Thus, the inhibition of antinociceptive response to intrathecal delta selective agonists by DOR antisense ODN correlates with the loss of DOR-ir in the superficial layers of the dorsal horn of the spinal cord.
Collapse
Affiliation(s)
- J Lai
- Department of Pharmacology, University of Arizona Health Sciences Center, Tucson 85724, USA.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- S T Crooke
- Isis Pharmaceuticals, Inc., Carlsbad, California 92008, USA
| |
Collapse
|
32
|
Hiller JM, Fan LQ, Simon EJ. Autoradiographic comparison of [3H]DPDPE and [3H]DSLET binding: evidence for distinct delta 1 and delta 2 opioid receptor populations in rat brain. Brain Res 1996; 719:85-95. [PMID: 8782867 DOI: 10.1016/0006-8993(96)00090-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The delta opioid ligands, [3H]DPDPE (delta 1) and [3H]DSLET (delta 2) were used in quantitative autoradiographic experiments to ascertain whether separate populations of delta opioid subtypes could be identified in rat brain. Densitometric image analysis showed a general similarity in delta 1 and delta 2 distributions. However, statistically significant differences in binding levels were observed in anatomically discrete regions. Examples of these regions and their delta 2/delta 1 ratio(s) are: dorsomedial hypothalamus (9.3), ventromedial hypothalamus (4.9), superior colliculis (2.7), medial division of bed nucleus stria terminalis (1.6-3.0), external cortex of the inferior colliculis (2.1), amygdaloid nuclei (1.5-2.1), cingulate cortex (1.8), CA1, CA2, and CA3 regions of Ammon's horn (1.6-2.0), dentate gyrus (1.7), laminar VI of the frontal, forelimb, hindlimb and parietal cortices (1.3-1.8), nucleus accumbens (1.4) and caudate/putamen (1.3). These findings provide evidence supporting the existence of distinct delta 1 and delta 2 opioid receptors.
Collapse
Affiliation(s)
- J M Hiller
- Department of Psychiatry, New York University Medical Center, NY 10016, USA
| | | | | |
Collapse
|
33
|
Leventhal L, Cole JL, Rossi GC, Pan YX, Pasternak GW, Bodnar RJ. Antisense oligodeoxynucleotides against the MOR-1 clone alter weight and ingestive responses in rats. Brain Res 1996; 719:78-84. [PMID: 8782866 DOI: 10.1016/0006-8993(96)00089-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
MOR-1 encodes a mu receptor. In an effort to establish the relationship of this cloned opioid receptor with ingestive behavior and analgesia in rats, the present study examined the actions of four antisense oligodeoxynucleotides aimed at exons 1 (AS1), 2 (AS2), 3 (AS3) and 4 (AS4) of the MOR-1 clone, as well as a mismatch antisense sequence (MS1). Rats were administered intracerebroventricular injections (10 micrograms/2 microliters) of each of the oligodeoxynucleotides on days 1, 3 and 5. Body weight and spontaneous food and water intake were monitored daily. In addition, 2-deoxy-D-glucose (2DG)-induced hyperphagia, central Angiotensin II (ANG-II) induced hyperdipsia and central morphine analgesia were examined 24 h following the last antisense injection. AS1, AS2, AS3 and AS4 each significantly reduced body weight (7-17 g), food intake (8-13 g) and water intake (11-23 ml), while the vehicle or MS1 conditions significantly increased weight (9-20 g) and produced smaller reductions (2-4 g) in food intake. None of the AS probes altered the magnitude of either 2DG-induced hyperphagia or ANG-II-induced hyperdipsia. Central morphine analgesia was reduced by pretreatment with AS1 and AS4, but not AS2, AS3 or MS1. The sensitivity of general feeding to all four exons suggest that the receptor responsible for this action is encoded by the MOR-1 clone. The differences between feeding and morphine analgesia raise the possibility that these two actions are mediated through different mu receptor subtypes. Our results also demonstrate the viability of the in vivo antisense technique in modulating opioid-mediated ingestive responses.
Collapse
Affiliation(s)
- L Leventhal
- Department of Psychology, Queens College, City University of New York, Flushing 11367, USA
| | | | | | | | | | | |
Collapse
|
34
|
Ogawa S, Pfaff DW. Application of antisense DNA method for the study of molecular bases of brain function and behavior. Behav Genet 1996; 26:279-92. [PMID: 8754251 DOI: 10.1007/bf02359384] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The antisense DNA method has been used successfully not only in vitro but also with in vivo systems to block effectively the expression of specific genes. An increasing number of studies have shown that antisense DNA administered directly into the brain can modify various kinds of behaviors. These findings strongly suggest that the antisense DNA method can be widely used as a powerful tool for the study of the molecular bases of behavior. In addition to traditional methods of behavioral genetics, the antisense DNA method may provide a new approach for the study of the effects of gene in behavioral function. In this article, we review recent studies reporting in vivo effects of antisense DNA on brain function and behavior.
Collapse
Affiliation(s)
- S Ogawa
- Laboratory of Neurobiology and Behavior, Rockefeller University, New York, New York 10021, USA
| | | |
Collapse
|
35
|
Guerrini R, Capasso A, Sorrentino L, Anacardio R, Bryant SD, Lazarus LH, Attila M, Salvadori S. Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B. Eur J Pharmacol 1996; 302:37-42. [PMID: 8790989 DOI: 10.1016/0014-2999(96)00067-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The single amino acid replacement of 2',6'-dimethyl-L-tyrosine in deltorphin B (H-Dmt-D-Ala-Phe-Glu-Val-Val-Gly-NH2) yielded high affinity for mu- and delta-binding sites. [Dmt1]Deltorphin B lacks activity at kappa-opioid binding sites. Bioactivity in vitro with guinea-pig ileum confirmed that [Dmt1]deltorphin B interacted with mu-opioid receptors by reducing electrically induced contractions in a naloxone-reversible manner and was 150-fold more potent than morphine and comparable to [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAGO). The inhibition of spontaneous contractions of rabbit jejunum provided evidence for delta-opioid receptor interaction. Analgesia (hot plate and tail flick tests) revealed that [Dmt1]deltorphin B was 180- to 200-fold more potent than morphine. Pretreatment with naloxone, naltrindole or H-Dmt-Tic-Ala-OH (a highly selective delta-opioid receptor antagonist) prevented [Dmt1]deltorphin B antinociception. Thus, [Dmt1]deltorphin B exhibited remarkably high dual affinity and bioactivity toward delta- and mu-opioid receptors.
Collapse
Affiliation(s)
- R Guerrini
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Italy
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Lazarus LH, Bryant SD, Salvadori S, Attila M, Sargent Jones L. Opioid infidelity: novel opioid peptides with dual high affinity for delta- and mu-receptors. Trends Neurosci 1996; 19:31-5. [PMID: 8787139 DOI: 10.1016/0166-2236(96)81864-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Deltorphins represent the paragon of delta-opioid-receptor ligands of natural origin, since they exceed the affinity and selectivity of the endogenous enkephalins by orders of magnitude. A series of opioid peptides have been developed in which the change in a single amino acid causes an extraordinary increase in mu-receptor binding while maintaining high affinity for the delta-receptor. The peptides appear to have a similar extended conformation in solution with a type-I beta-turn in the N-terminus region, suggesting that tertiary architecture plays a pivotal role in enabling the peptide to bind indiscriminately to mu- and delta-receptors. These dual-affinity peptide ligands can serve to mask delta- and mu-receptors while mapping kappa-receptors in the nervous system, to provide an understanding of the differences and similarities in the structure of the binding domains of delta- and mu-receptors, and might lead to a comprehensive new regime for the clinical management of acute and chronic pain.
Collapse
Affiliation(s)
- L H Lazarus
- Peptide Neurochemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | | | | |
Collapse
|
37
|
Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 1996; 39:185-8. [PMID: 8866695 DOI: 10.1016/0361-9230(95)02092-6] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Pharmacological data from several laboratories support a modulatory role for the delta opioid receptor in morphine analgesia, tolerance, and physical dependence. We examined the role of the delta opioid receptor in these processes using an in vivo antisense strategy in mice. Intracerebroventricular administration of a 20mer antisense or a mismatch control oligodeoxynucleotide (ODN) targeting the mRNA of the cloned delta opioid receptor (DOR-1) for 3 days did not affect baseline nociceptive thresholds or morphine analgesia compared to untreated or saline-treated mice. However, dose-response studies indicate that the induction of morphine tolerance following 3 days of chronic morphine administration was blocked in antisense but not mismatch ODN or saline-treated mice. Antisense ODN treatment also blocked the development of acute morphine dependence, whereas similar protection was not afforded to mice treated with saline or mismatch ODN. This study demonstrates the relevance of the cloned DOR-1 in morphine tolerance and dependence and provides new evidence for a modulatory role of the delta opioid receptor using this novel approach.
Collapse
Affiliation(s)
- B Kest
- Department of Pharmacology, Cornell University Medical College, New York, NY 10021, USA
| | | | | | | |
Collapse
|
38
|
Grailhe R, Hen R. 5-HT receptor knockouts: Constitutive, inducible or tissue-specific. ACTA ACUST UNITED AC 1995. [DOI: 10.1016/1044-5765(95)90003-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
Cha XY, Xu H, Ni Q, Partilla JS, Rice KC, Matecka D, Calderon SN, Porreca F, Lai J, Rothman RB. Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes. REGULATORY PEPTIDES 1995; 59:247-53. [PMID: 8584761 DOI: 10.1016/0167-0115(95)00095-s] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Prior work in our laboratory has identified putative subtypes of delta (delta cx-1, delta cx-2, delta ncx-1, delta ncx-2) and kappa 2 (kappa 2a and kappa 2b) receptors. Previous studies showed that chronic (three day) i.c.v. administration of antisense oligodeoxynucleotide to the cloned delta opioid receptor selectively decreased [3H][D-Ala2,D-Leu5]enkephalin binding to the delta ncx site, not the delta cx-2 site. The present study extends this work by demonstrating that delta antisense DNA selectively affects the delta ncx-2 site sparing the other putative delta receptor subtypes and kappa 2 receptor subtypes. This selectivity is not due to anatomically specific effects of delta antisense DNA since autoradiograms show that delta binding is reduced in all regions of the brain after chronic i.c.v. administration of delta antisense DNA. These data strongly suggest that the delta cx-1, delta cx-2, delta ncx-1, kappa 2a and kappa 2b binding sites are different proteins than the delta ncx-2 binding site, which, based on its sensitivity to delta antisense DNA, is synonymous to the cloned delta opioid receptor. Viewed collectively, these data suggest that administration of delta antisense DNA, and by extension other receptor-selective antisense DNA, is a powerful approach to distinguishing between postulated receptor subtypes.
Collapse
Affiliation(s)
- X Y Cha
- Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, MD 21224, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Mizoguchi H, Narita M, Nagase H, Tseng LF. Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming. REGULATORY PEPTIDES 1995; 59:255-9. [PMID: 8584762 DOI: 10.1016/0167-0115(95)00101-g] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The type of opioid receptors in the spinal cord involved in antinociception induced by cold water swimming (CWS) was studied in male ICR mice. Mice were submitted to CWS for 3 min and antinociception was measured 7 min after the CWS by the tail-flick test. Intrathecal (i.t.) injection of naltrindole (NTI, 5 micrograms) which blocked i.t. DPDPE ([D-Pen2,D-Pen5]en-kephalin, 5 micrograms)-induced antinociception, blocked the CWS-induced antinociception. On the other hand, i.t. injection of CTOP (D-Phe-Cys-Try-D-Try-Orn-Thr-Pen-Thr-NH2, 50 ng) and norbinaltorphimine (nor-BNI, 5 micrograms) which blocked i.t. DAMGO ([D-Ala2,NHPhe4,Gly-ol]enkephalin, 10 ng)- and U50,488H (trans(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide, 75 micrograms)-induced antinociception, respectively, did not block CWS-induced antinociception. Intrathecal pretreatment with antisense oligodeoxynucleotide to delta-opioid receptor mRNA (delta-AS oligo, 163 pmol) once a day for 1 to 3 days caused a time-dependent attenuation of CWS-induced antinociception. delta-AS at doses from 1.6 to 163 pmol pretreated i.t. for 3 days caused a dose-dependent blockade of CWS-induced antinociception. However, i.t. pretreatment with mismatch oligodeoxynucleotide (MM oligo, 163 pmol) for 3 days did not affect the CWS-induced antinociception. The results indicate that CWS-induced antinociception is mediated by the stimulation of delta-opioid receptors in the spinal cord.
Collapse
MESH Headings
- Amino Acid Sequence
- Analgesia/methods
- Animals
- Base Sequence
- Cold Temperature
- Injections, Spinal
- Male
- Mice
- Mice, Inbred ICR
- Molecular Sequence Data
- Oligonucleotides, Antisense/pharmacology
- Pain/physiopathology
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/physiology
- Receptors, Opioid, kappa/physiology
- Receptors, Opioid, mu/physiology
- Spinal Cord/drug effects
- Swimming
Collapse
Affiliation(s)
- H Mizoguchi
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226, USA
| | | | | | | |
Collapse
|
41
|
Suzuki S, Pilowsky P, Minson J, Arnolda L, Llewellyn-Smith I, Chalmers J. Antisense to thyrotropin releasing hormone receptor reduces arterial blood pressure in spontaneously hypertensive rats. Circ Res 1995; 77:679-83. [PMID: 7554113 DOI: 10.1161/01.res.77.4.679] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We report in the present study the effect of intrathecal treatment with antisense oligonucleotides complementary to thyrotropin releasing hormone (TRH) receptor mRNA on the pressor response to intrathecal administration of TRH and on resting arterial blood pressure in Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). In 16-week-old male WKY rats, 18-base phosphodiester antisense or mismatch oligonucleotides to TRH receptor mRNA (100 micrograms per day) were injected intrathecally for 3 days. Twenty-four hours after the last injection, the magnitude of the pressor response to intrathecal TRH (10 micrograms) was significantly smaller in the antisense-treated group (n = 7) compared with mismatch-treated controls (n = 7) (change in mean arterial pressure, +20.3 +/- 3.0 versus +32.6 +/- 2.5 mm Hg, P < .01). No differences were observed in the pressor responses to injection of N-methyl-D-aspartic acid. Resting arterial blood pressure was unaffected by antisense treatment in WKY rats. In separate experiments, 16-week-old male SHR were treated with antisense (n = 7) or mismatch (n = 6) oligonucleotides for 3 days. Mean resting arterial blood pressure was significantly reduced by treatment with antisense oligonucleotides (from 157 +/- 4.8 to 119 +/- 8.8 mm Hg, P < .01), but no significant changes were observed in mismatch-treated animals. Our results suggest that the expression of TRH receptors in spinal sympathetic preganglionic neurons can be selectively reduced by intrathecal treatment with antisense oligonucleotides and that TRH projections to sympathetic preganglionic neurons play an important role in the elevation of arterial blood pressure in SHR.
Collapse
Affiliation(s)
- S Suzuki
- Department of Medicine, Flinders Medical Centre, Adelaide, Australia
| | | | | | | | | | | |
Collapse
|
42
|
Minami M, Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 1995; 23:121-45. [PMID: 8532211 DOI: 10.1016/0168-0102(95)00933-k] [Citation(s) in RCA: 216] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Opiates like morphine and endogenous opioid peptides exert their pharmacological and physiological effects through binding to their endogenous receptors, opioid receptors. The opioid receptors are classified into at least three types, mu-, delta- and kappa-types. Recently, cDNAs of the opioid receptors have been cloned and have greatly advanced our understanding of their structure, function and expression. This review focuses on the recent advances in the studies on opioid receptors using the cloned cDNAs. We describe the molecular cloning of the opioid receptor gene family and studies of the structure-function relationships, modes of coupling to second messenger systems, pharmacological effects of antisense oligonucleotide and anatomical distributions of opioid receptors.
Collapse
Affiliation(s)
- M Minami
- Department of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Japan
| | | |
Collapse
|
43
|
Abstract
In recent years, cloning has revealed the existence of no less than 14 mammalian 5-HT receptors, as well as evidence that isoforms of the 5-HT4 and 5-HT7 receptors are generated by alternative splicing. In addition, molecular biology techniques have provided new tools with which to study the function of 5-HT receptors. For example, new technologies are emerging that will allow the generation of either inducible or tissue-specific knockouts (or both). In this review José Lucas and René Hen focus on the characteristics of the most recently cloned receptors and the contribution of molecular biology to the understanding of 5-HT receptor function.
Collapse
Affiliation(s)
- J J Lucas
- Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA
| | | |
Collapse
|
44
|
Abstract
Opioid receptors are the primary sites of actions of opiates and endogenous opioid peptides, which have a wide variety of pharmacological and physiological effects. The opioid receptors are classified into at least three subtypes, mu, delta, and kappa, and their cDNAs have been cloned. In this review, we describe the molecular cloning of opioid receptor gene family and studies of the structure-function relationships, modes of coupling to second messenger systems, pharmacological effects of antisense oligonucleotides, and anatomical distribution of opioid receptor mRNAs.
Collapse
MESH Headings
- Amino Acid Sequence
- Central Nervous System/metabolism
- Ganglia, Spinal/metabolism
- Molecular Sequence Data
- RNA, Messenger/analysis
- Receptors, Opioid/genetics
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/genetics
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/genetics
- Receptors, Opioid, mu/metabolism
- Second Messenger Systems/physiology
- Sequence Homology, Amino Acid
Collapse
Affiliation(s)
- M Satoh
- Department of Molecular Pharmacology, Kyoto University, Japan
| | | |
Collapse
|
45
|
Cha XY, Xu H, Rice KC, Porreca F, Lai J, Ananthan S, Rothman RB. Opioid peptide receptor studies. 1. Identification of a novel delta-opioid receptor binding site in rat brain membranes. Peptides 1995; 16:191-8. [PMID: 7784248 DOI: 10.1016/0196-9781(94)00182-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Our laboratory was among the first to propose the existence of delta receptor subtypes: a delta site thought to be associated with a mu-delta-opioid receptor complex termed the delta cx binding site and delta site not associated with the mu-delta-opioid receptor complex, termed the delta ncx site. In previous studies, we assayed the delta cx site with [3H][D-Ala2,D-Leu5]enkephalin using rat brain membranes depleted of delta ncx sites by pretreatment with the site-directed acylating agent, (+)-trans-SUPERFIT. In the present study, we investigated, using (+)-trans-SUPERFIT-pretreated membranes, the possibility of heterogeneity of the delta cx binding site. Two sites were resolved: the delta cx-1 site at which mu ligands are potent noncompetitive inhibitors and delta ligands are weak competitive inhibitors, and the delta cx-2 site where delta ligands are potent and mu ligands are weak, mixed competitive-noncompetitive inhibitors. Although the delta cx-2 site has a delta-like ligand-selectivity profile, several experiments distinguished it from the delta ncx site. Two lines of evidence suggest that the delta ncx site corresponds to the cloned delta receptor. One, the delta receptor was cloned from the NG108-15 cell line, and this receptor, like the delta ncx binding site, irreversibly binds SUPERFIT and (+)-trans-SUPERFIT. Secondly, administration of delta-antisense DNA selectively decreases delta ncx binding. Viewed collectively, the major finding of this study is the discovery of a novel SUPERFIT-insensitive and delta-antisense-insensitive delta cx-2 binding site.
Collapse
MESH Headings
- Analgesics/pharmacology
- Animals
- Base Sequence
- Binding Sites
- Binding, Competitive
- Brain/metabolism
- Cell Membrane/metabolism
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalin, Leucine-2-Alanine/metabolism
- Enkephalins/pharmacology
- Kinetics
- Molecular Sequence Data
- Morphine/pharmacology
- Oligonucleotides, Antisense/chemical synthesis
- Oligonucleotides, Antisense/pharmacology
- Rats
- Receptors, Opioid, delta/analysis
- Receptors, Opioid, delta/metabolism
Collapse
Affiliation(s)
- X Y Cha
- Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD 21224, USA
| | | | | | | | | | | | | |
Collapse
|
46
|
Chapter 2. Centrally Acting Analgesics. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1995. [DOI: 10.1016/s0065-7743(08)60915-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|